EA
EIGR

Emerald Acquisition’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Emerald Acquisition’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$169K Buy
+421
New +$215K ﹤0.01% 2732

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Emerald Acquisition's EIGR Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2016: 421 shares worth $169K. The stake represents ﹤0.01% of the portfolio and ranks #2732 among its holdings.

47 funds tracked by Wall St. Rank hold EIGR as of Q3 2016.

  • Emerald Acquisition held 421 shares of Eiger BioPharmaceuticals, Inc. worth $169K as of Q3 2016.
  • Eiger BioPharmaceuticals, Inc. was a new Emerald Acquisition position in Q3 2016.
  • Eiger BioPharmaceuticals, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2732 holding.
  • 47 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.